As shown in a recent prospective study in 150 HBsAg-negative anti-HBc-positive patients undergoing cyclic rituximab-containing chemotherapy for lymphoma, the incidence of HBVr was 10% and the incidence of hepatitis flare was 6% [33]. This evidence concerns the gene KRT88P and Hepatitis.